CONTRAFECT Corp
DelistedCIK 1478069fmd_1MAAW16JG44ZQRK2ZG1QW56H2XManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Dec 31, 2023, 43 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | (2) | (12) | 0 | – | – | – | – | – | – | – |
| Research and development | 9 | 9 | 15 | 22 | 17 | 22 | 18 | 23 | 36 | 45 |
| Total operating expenses | 19 | 17 | 25 | 34 | 27 | 31 | 28 | 34 | 47 | 65 |
| Operating income | (19) | (17) | (25) | (34) | (27) | (31) | (28) | (34) | (47) | (65) |
| Interest expense | 2 | 12 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (4) | (13) | (0) | 5 | 11 | (7) | 15 | 6 | 27 | (1) |
| Net income | (24) | (30) | (25) | (29) | (16) | (38) | (13) | (28) | (20) | (65) |
| Net income to common shareholders | (24) | (35) | (25) | (29) | (16) | – | – | – | – | – |